Spring Bank Pharmaceuticals Inc

Spring Bank Pharmaceuticals — IPO Roadshow (April 2016)

19 slides from Spring Bank Pharmaceuticals's IPO roadshow presentation, Apr 29, 2016

  1. Slide 1: Corporate Presentation April 2016

    Corporate Presentation April 2016 Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated April 29, 2016 Relating to Preliminary Prospectus dated April 26, 2016 Registration Statement No. 333-208875

  2. Slide 2: Forward Looking Statements and Other Legal Matters

    Forward Looking Statements and Other Legal Matters We have filed a registration statement on Form S-1 (Registration No. 333-208875) (including a preliminary prospectus) with the SEC for the offering to which this presentation relates. The registration statement has not yet become effective. Before y

  3. Slide 3: Executive Management Team

    Executive Management Team Name Title Prior Experience Martin Driscoll Chief Executive Officer Kris Iyer, PhD Chief Scientific Officer & Co-Founder Nezam Afdhal, MD Chief Medical Officer Jonathan Freve, CPA Chief Financial Officer Authored >100 issued and filed patents - Current Scientific Advisory B

  4. Slide 4: Spring Bank Investment Opportunity

    Spring Bank Investment Opportunity Lead asset, SB 9200, is a first-in-class, selective immunomodulator with potential pan-viral applications Multiple anticipated milestones expected during the use of proceeds period from this offering SB 9200 could become a backbone therapy for the treatment of chro

  5. Slide 5: Program Candidate Indication / Therapeutic Area

    Program Candidate Indication / Therapeutic Area Discovery Preclinical Phase 1 Phase 2 Anticipated Milestones SB 9200 HBV* Phase 2a Initiation in H1 2016 HCV Seek Collaborations RSV† Initiate Clinical Development HIV Latency† Establish Preclinical Proof-of-Principle HDV† Establish Preclinical Proof-o

  6. Slide 6: Anticipated Milestones

    Report additional results from SB 9200 Phase 2a HBV trial by H2 2017 Initiate SB 9200 Phase 2b HBV trial (subject to results of Phase 2a, additional funding & discussions w/ regulatory authorities) Phase 1 HCV data on SB 9200 presented at the 2015 AASLD meeting Clinical trial collaboration announced

  7. Slide 7: SB 9200 – Phase 1 Proof-of-Principle Study in HCV Patients

    SB 9200 – Phase 1 Proof-of-Principle Study in HCV Patients Oral bioavailability, safety and antiviral activity in the treatment of HCV patients observed Phase 1 study in treatment naïve HCV patients Part A: Single ascending doses of 100 – 800 mg, N=8 Part B: Multiple ascending doses 200 – 900 mg onc

  8. Slide 8: Chronic HBV Remains a Major, Global Unmet Medical Need

    Chronic HBV Remains a Major, Global Unmet Medical Need Sources: WHO, CDC & Hepatitis B Foundation Feb 2014. Chronic HBV infection prevalence: Approximately 240M globally, with approximately 14M in the U.S. and Europe More than 780,000 people worldwide die every year due to complications of chronic H

  9. Slide 9: SB 9200 – A Novel Candidate for HBV

    SB 9200 – A Novel Candidate for HBV A differentiated therapy with potential to drive functional cure in HBV patients Contemporary HBV drugs are ineffective at reducing/clearing surface antigens Current oral antiviral therapies including polymerase inhibitors Baraclude (entecavir) and Viread (tenofov

  10. Slide 10: SB 9200 in Woodchuck Model for HBV

    SB 9200 in Woodchuck Model for HBV Data supports clinical evaluation of SB 9200 in HBV The ideal preclinical model for studying HBV The woodchuck hepatitis virus (WHV) and its host, the American woodchuck, is accepted as the most suitable animal model for human HBV infection due to similarities in m

  11. Slide 11: SB 9200 Demonstrates Potent Antiviral Activity in Chronically WHV-Infected Woodchucks

    SB 9200 Demonstrates Potent Antiviral Activity in Chronically WHV-Infected Woodchucks In study subsequent entecavir treatment augments SB 9200’s ability to reduce viremia Recent third party study evaluating recombinant IFN-α in woodchucks reported an average decline in serum WHV DNA of approximately

  12. Slide 12: Treatment with SB 9200 Leads to Decline in Serum WHsAg Levels

    Treatment with SB 9200 Leads to Decline in Serum WHsAg Levels in Chronically WHV-Infected Woodchucks Reduction of serum WHsAg in sequential dosing study believed to support thesis to combine SB 9200 with oral antiviral agents Four of five woodchucks in the sequential dosing study of SB 9200 and ente

  13. Slide 13: Early Viral Kinetics Predictive of Response and Eventual HBsAg Loss

    Early Viral Kinetics Have Been Predictive of Response and Eventual HBsAg Loss in HBV Patients Reduction of HBsAg following 12 weeks of PEG-IFN-α treatment is a key predictor of functional cure In clinical studies evaluating PEG-IFN-α–based regimens, decline of HBsAg at Week 12 was highly predictive

  14. Slide 14: Phase 2 Clinical Trials in HBV

    Phase 2 Clinical Trials of SB 9200 in HBV Clinical trial collaboration with Gilead to evaluate SB 9200 with nucleotide analog Viread Randomized, placebo controlled, multiple ascending dose trial Up to 100 non-cirrhotic HBV subjects, randomized 4:1 between SB 9200 and placebo Stratification based on

  15. Slide 15: Summary for HBV

    Summary of SB 9200 for HBV Oral, first-in-class immunomodulator for the treatment of HBV Proof-of-principle for SB 9200 established in Phase 1 study in HCV patients Biomarker data affirmed novel MOA through induction of intracellular interferon signaling pathways Antiviral activity was observed at a

  16. Slide 16: Offering Summary

    Offering Summary Issuer Spring Bank Pharmaceuticals, Inc. Proposed Ticker / Exchange SBPH / NASDAQ Proposed Offering Size $15.0 Million Expected Shares Offered 1,154,000 (100% Primary Shares) Filed Range $12.00 - $14.00 per share Underwriters Option 15.0% Insider Participation Certain executive offi

  17. Slide 17: Financial Highlights

    Financial Highlights Founded in 2002 $40 million of funding since inception $13 in million cash, cash equivalents and marketable securities as of 12/31/2015 Use of proceeds Conduct Phase 2a clinical trial of SB 9200 in chronic HBV Working capital and general corporate purposes 16

  18. Slide 18: Spring Bank Pharmaceuticals Highlights

    Lead asset, SB 9200, is a first-in-class, selective immunomodulator with potential pan-viral applications Spring Bank Pharmaceuticals Highlights Chronic HBV remains a major, global unmet medical need with opportunity for new treatments that can achieve functional cure - initiation of Ph 2a clinical

  19. Slide 19: Thank you!

    Thank you! PS spring bank

Spring Bank Pharmaceuticals — IPO Roadshow (April 2016) on 6ix